Skip to content

F. Graf Finckenstein

Bristol-Myers Squibb (United States)

1 paper in the Anchorcite directory, published in 2015, cited 9,473 times in total.

Research topics

Frequent co-authors

Papers

  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations

    BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…

Metadata from OpenAlex (CC0).